Restaurants may face loss of revenue because of the prescription drugs, whereas fitness centers could benefit.
Ozempic, a diabetes medication by Novo Nordisk, has gained popularity for its weight loss effects, sparking debate.
The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...
GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...
"Additionally, GLP-1 agonists can cause gastrointestinal side effects like nausea, vomiting, and diarrhoea. These symptoms ...
These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback